Dendritic cells (DCs) have a critical role in the induction of antigen-specific immune responses, transporting antigens from peripheral tissue to regional lymph nodes where they interact with antigen-specific T lymphocytes. Recent studies revealed that the efficacy of the T cell-dependent immune response depends on the lifespan of the antigen-presenting DCs in the lymph nodes. Here, we succeeded in engineering long-lived antigen-presenting DCs via Bcl-x L -derived hyperactive mutant antiapoptotic protein (Bcl-x FNK ) gene transfer. In a B16BL6 melanoma model, these long-lived DCs exerted potent antitumor immunity that depended mainly on antigenspecific cytotoxic T lymphocytes. Furthermore, in vivo longevity of the long-lived DC vaccine led to antigen-specific activation of interferon-g-producing CD4
Introduction
Dendritic cells (DCs), the most powerful antigen-presenting cells known, have a pivotal role in the initiation of immune responses against tumors and pathogens. 1 After antigen capture, DCs mature in response to inflammatory stimuli such as upregulation of major histocompatibility complex (MHC)-and costimulatory molecules. Antigen-bearing DCs then migrate to draining lymph nodes (LNs) and efficiently stimulate antigen-specific T cells via MHC molecules. 2 Despite the widespread use of DCs in tumor vaccination protocols, 3 the limited clinical success of DC vaccines necessitates new methodologies for improving DC vaccine potency. 4 Several methods for manipulating antigen-presenting DCs have been developed in experimental studies and applied in clinical trials. As T-cell priming is drastically affected by the expression levels of costimulatory molecules on DCs, many DC-based vaccine strategies are focused on manipulating the DC activation state. Activated antigen-bearing DCs are unexpectedly short lived in draining LNs, 5 however, and phagocytosis or reprocessing of antigens from dead DCs to immature antigen-presenting cells may lead to tolerance. 6 Thus, the lifespan of DCs in vivo is a critical factor for the regulation of antitumor immunity, and the short lifespan of DC vaccines limits the efficiency of DC-based cancer immunotherapy. 7, 8 Although all the factors that regulate DC lifespan are not yet known, ligands for Toll-like receptors and T cell-expressed costimulatory molecules (for example, CpG, CD40L and TRANCE) prolong the survival of DCs through the expression of antiapoptotic factors, such as Bcl-2 and Bcl-x L . [9] [10] [11] [12] [13] [14] Furthermore, Bcl-x Ldeficient DCs, which are isolated from Bcl-x L fl/fl mice, fail to induce effective immune responses in vivo, which correlates with their rapid disappearance from the draining LNs due to apoptosis. 13 These findings led us to speculate that DC-based vaccination could be enhanced by engineering DCs to overexpress antiapoptotic protein using gene-transfer methods to inhibit apoptosis and prolong the survival of antigen-presenting DCs in vivo.
Among the various methodologies available for modifying DCs, the gene-transduction technique is a promising approach. We previously reported that RGD fiber-mutant adenoviral vector (AdRGD), which targets a v -integrin during attachment to cells by insertion of the RGD peptide into the HI-loop of the fiber knob, 15 exerts efficient gene transduction in murine and human DCs. [16] [17] [18] Therefore, in the present study, we prepared long-lived DCs by AdRGD-mediated cotransduction of an antiapoptotic gene (Bcl-x L or Bcl-x FNK ; a hyperactive mutant form of Bcl-x L constructed by inducing a point mutation 19 ) and an antigen-encoding gene. Furthermore, we tested the potential of this immunization strategy to improve antitumor immunity against mouse B16BL6 melanoma.
Results

In vitro survival and antigen-presentation assay
To analyze whether Bcl-x FNK -or Bcl-x L -gene transduction can prolong the lifespan of antigen-bearing DCs, we first analyzed DC survival in vitro in growth factor-starved cultures using a propidium iodide (PI)-staining method. The Bcl-x FNK , Bcl-x L or luciferase-expressing DCs (designated FNK/DCs, Bcl-x L /DCs and Luc/DCs, respectively), were prepared using the corresponding AdRGD and further cultured without granulocyte macrophage colony-stimulating factor (GM-CSF). In the DC survival assay, Luc/DCs and mock DCs were used as controls. The expression of Bcl-x L and Bcl-x FNK protein was confirmed by western blotting analysis using A549 cells (data not shown). The analysis of cell viability demonstrated that 4 days after transduction (day 4), the percentage of viable FNK/DCs and Bcl-x L /DCs was significantly higher than that of mock DCs or Luc/DCs ( Figure 1a) . Furthermore, the survival rate of mock DCs or Luc/DCs gradually decreased, whereas more than 50% of the FNK/DCs and Bcl-x L /DCs were still alive in 7-day cultures. As Bcl-x L prevents apoptosis by preventing cytochrome c release from the mitochondria, it has been speculated that Bcl-x FNK gene transduction might protect DCs from apoptosis induced by cytochrome c release from the mitochondria to the cytosol. Our preliminary experiments revealed that treatment of control cells, a luciferase gene-transduced DC cell line (DC2.4), and mock cells with staurosporine resulted in a dose-dependent reduction of cell viability (data not shown). In contrast, however, DC2.4 cells overexpressing Bcl-x FNK slightly resisted the decrease in cell viability. Thus, the results indicated that FNK/DCs and Bcl-x L /DCs were more resistant to apoptosis and cytokine-starved conditions than Luc/DCs and mock DCs.
We then analyzed whether prolongation of the DC lifespan by overexpressing antiapoptotic protein prolonged their MHC class I antigen presentation. DCs cotransduced with ovalbumin (OVA)-expressing AdRGD (AdRGD-OVA) and AdRGD-Bcl-x FNK (FNK+O-VA/DC) or AdRGD-Bcl-x L (Bcl-x L +OVA/DCs) were prepared using the corresponding AdRGDs and further cultured without GM-CSF. At several time points after gene transduction, transduced DCs were fixed with glutaraldehyde and cocultured with OVA/MHC class Icomplex reactive CD8-OVA1.3 cells for 24 h, and interleukin (IL)-2 production from CD8-OVA1.3 cells in the culture supernatant was quantified by enzyme-linked immunosorbent assay (ELISA). The MHC class Imediated OVA presentation levels of FNK+OVA/DCs, Bcl-x L +OVA/DCs and DCs transduced with AdRGD-OVA alone (OVA/DCs) were highest at day 2, and then gradually declined (Figure 1b) . At day 7, OVA presentation levels of OVA/DC were below the detection limit, whereas OVA presentation levels of FNK+OVA/DCs and Bcl-x L /DCs remained at approximately 40% of that at day 2.
These results clearly demonstrated that genetically engineered DCs to express antiapoptotic protein were a useful strategy for prolonging DC lifespan. Furthermore, AdRGD-mediated antiapoptotic gene transduction also prolonged the period of antigen presentation without affecting the DC antigen-presentation machinery. Cr-release assay. At 1 week after immunization of C57BL/6 mice with various vaccines, the splenocytes were restimulated in vitro with inactivated E.G7-OVA for CTL expansion. The OVA-specific CTL activity of in vitro restimulated effector cells was enhanced in mice vaccinated with OVA/DC as compared with mice vaccinated with mock DCs. On the other hand, the most effective CTL activity was recognized in the FNK+OVA/DC and Bcl-x L +OVA/DC immunized groups (Figure 2b ). These lytic activities were E.G7-OVA-specific because the effector cells prepared from mock DC-vaccinated mice did not kill parental EL4 cells.
These results suggested that immunization with longlived DCs primed more efficient antigen-specific CTLs and tumor-growth inhibition than conventional DCs transduced with antigen genes alone. Together, our data clearly showed that the FNK/DCs were the most immunogenic DC vaccines in the artificial E.G7-OVA tumor model.
Examination of the induction mechanism of long-lived DC vaccine-mediated antigen-specific tumor immunity using murine B16BL6 melanoma
Although long-lived DCs induced highly efficient antitumor immunity in an artificial tumor-specific antigen (OVA), the applicability of this technology for clinical use depends upon its efficacy with naturally occurring TAA, and the mechanism of action must be clarified. Thus, we tested the antitumor efficacy and induction mechanism using a murine B16BL6 melanoma model, focusing on the FNK/DC vaccine. DCs cotransduced with AdRGDgp100 and AdRGD-Bcl-x FNK (FNK+gp100/DC) or with AdRGD-gp100 alone (gp100/DCs) were prepared and intradermally injected into the right flanks of C57BL/6 mice. In the prophylactic vaccine protocol that targets the melanoma-associated tumor antigen, gp100, tumor growth was more powerfully inhibited in mice immunized with the FNK+gp100/DCs than in mice immunized with gp100/DCs, which were transduced with only the gp100 gene ( Figure 3) . Thus, the long-lived DC vaccine is a clinically useful strategy for eradicating self TAA-expressing tumors and murine artificial (OVA) tumors.
We next performed in vivo depletion studies of CD4 + T cells, CD8 + T cells and natural killer (NK) cells in C57BL/6 mice vaccinated with FNK+gp100/DCs to determine the cell subsets involved in the effector function. B16BL6 tumor growth was still slightly inhibited in FNK+gp100/DC-vaccinated mice depleted of either CD4 + T cells or NK cells (Figure 4a ). On the other hand, the tumor growth rate was noticeably higher in CD8-depleted mice compared with either CD4-or NKdepleted mice, or nondepleted mice; and depletion of CD8 + and CD4 + T lymphocytes from tumor-bearing mice completely blocked the protective effect of FNK+gp100/ DC. These results indicated that gp100-specific CD8 Cr-release assay. Similar experiments were performed twice.
Engineering of highly immunogenic long-lived DC vaccines T Yoshikawa et al
CTLs are critical for tumor growth inhibition, and that CD4 + T cells contribute to their priming and activation of antitumor immunity. Consistent with this result, an intracellular staining experiment showed that B16BL6-reactive interferon (IFN)-g producing CD4 + and CD8 + T cells populations, which have crucial roles in antitumor cellular immunity, were easily detected in mice immunized with FNK+gp100/DCs (Figure 4b ).
These results demonstrated that antiapoptotic proteintransduced DCs were superior vaccines compared with the conventional DC vaccine, which is transduced with the antigen-encoding gene alone, in the B16BL6 melanoma and E.G7-OVA tumor models. Furthermore, immunization with FNK/DCs more efficiently primed antigen-specific IFN-g-producing T cells as compared with conventional antigen-gene modified DCs. Thus, CD8 + T cells, but not NK cells, have a critical role in the antitumor effect generated by the DC vaccine combined with Bcl-x FNK gene transduction using AdRGD, and activation of CD8 + effector cells were dependent on the helper function of CD4 + T cells.
In vivo migratory ability of FNK/DCs
To determine whether transduction of antiapoptotic molecules improves DC survival in vivo, we investigated the migratory ability of AdRGD-Bcl- 
Discussion
The findings of the present study demonstrate that vaccination with TAA-expressing DCs transduced with antiapoptotic Bcl-x L or Bcl-x FNK protein increased TAAspecific antitumor immune responses in mice. These Bclx L -or Bcl-x FNK -transduced DCs were highly resistant to spontaneous cell death, leading to prolonged MHC class I-mediated antigen presentation in vitro. This resulted in enhanced DC-mediated tumor vaccine potency, as well as enhanced CTL priming and tumor-growth inhibition. Furthermore, this improvement in the long-lived FNK/ DC vaccine potency might be due to a prolonged in vivo DC lifespan and antigen-presentation duration, which led to enhanced TAA-specific CD8 + T-cell priming. To the best of our knowledge, this is the first report demonstrating that modulation of apoptosis in DCs by gene transduction using AdRGD-mediated Bcl-x L or -Bcl-x FNK can be used to prolong DC survival, increase the MHC class I-mediated antigen presentation period and improve DC vaccine potency against syngeneic murine B16BL6 melanoma.
Three major apoptotic pathways originating from three separate subcellular compartments have been identified. The receptor-mediated pathway involves the interaction of plasma membrane death receptors with their ligands. 20 The mitochondrial pathway involves the functional incapacitation of the mitochondria by proapoptotic Bcl-2 family members. 21 Finally, the endoplasmic reticulum pathway 22 is triggered by the application of various forms of stress that result in caspase activation. DC apoptosis is suggested to be induced by several pathways, such as antigen-specific T cell-induced apoptosis, which interacts with DCs, 23 or naturally occurring cell death through self-renewal machinery after completing its mission, such as antigen presentation or activation of acquired immune responses. 24 In fact, in Figure 3 Vaccine efficacy of dendritic cells (DCs) cotransduced with gp100 and Bcl-x FNK gene against B16BL6 melanoma challenge. FNK+gp100/DC and gp100/DC were prepared using corresponding RGD fiber-mutant adenoviral vector (AdRGDs) at 25 multiplicities of infection (MOI), and then cultured for 24 h. C57BL/6 mice were immunized by intradermal injection of transduced DCs into right flank at 1.5 Â 10 6 cells, and then B16BL6 cells were inoculated into the left flank intradermally at 5 Â 10 4 cells 1 week post vaccination. The size of tumors was assessed using microcalipers three times per week. Each point represents the mean ± s.e. from 5 to 10 mice.
Engineering of highly immunogenic long-lived DC vaccines
T Yoshikawa et al the PI3k/Akt pathway, Bcl-2 or Bcl-x L might have an essential role in regulating the DC lifespan. [12] [13] [14] 25 The DC lifespan can significantly influence immune responses by affecting the duration of DC stimulation of lymphocytes, but the detailed molecular mechanisms and relationship between DC lifespan and the above-mentioned three 6 cells. The vaccinated mice were divided into four groups receiving an injection of either depleting anti-CD8 mAb, anti-CD4 mAb or anti-ASGM1 antisera. Details on the experimental procedure and mAbs are described in Materials and methods. The animals were then challenged with B16BL6 cells on day 7 and monitored for tumor development. The data represent the mean ± s.e. of 5-10 mice. (b) Intracellular staining assay. FNK+gp100/DCs, gp100/DCs or mock DCs were vaccinated once intradermally into C57BL/6 mice at 1.5 Â 10 6 cells. One week after single immunization, lymphocytes were prepared from these mice and restimulated with MMC-inactivated B16BL6 cells for 24 h. The number of IFN-g secreting CD4 + or CD8 + T cells was analyzed by intracellular cytokine staining followed by flow cytometry analysis with acquisition of 30 000 events. Similar results were obtained from two independent experiments.
Engineering of highly immunogenic long-lived DC vaccines T Yoshikawa et al major apoptotic pathways remain unknown. Thus, although we propose Bcl-x FNK or Bcl-x L gene transduction as an attractive approach for engineering long-lived DC vaccines, more detailed analysis of DC lifespan is required to provide useful information for creating optimal long-lived DC vaccines.
Although the Bcl-x FNK gene was the most effective for increasing the antitumor effect, the utilization of the antiapoptotic gene for clinical applications might be limited because these antiapoptotic proteins are also implicated as contributors to oncogenic transformation. We evaluated the tumorigenesis of FNK/DC and Bcl-x L / DC using a colony formation assay in soft agar that is predictive of tumorigenic capability (data not shown). The colony formation assay suggested that the antiapoptotic genes used in this study did not transform bone marrow-derived DCs. These results suggested that AdRGD-mediated antiapoptotic gene transduction was a highly effective and safe therapeutic approach to enhance DC-vaccine potency. Alternatively, the AdRGD-mediated short interfering RNA transduction approach 26 that targets proapoptotic proteins, such as BAK/BAX, might be useful without the oncogenic concerns associated with the transduction of antiapoptotic protein genes.
Recently, several approaches, similar to ours, were reported and suggested that gene gun-or lipofectionmediated antiapoptotic gene or short interfering RNA that targets proapoptotic gene transduction increased DC-based vaccine potency.
25,27-29 Lipofection-or gene gun-mediated gene transduction, however, is highly limited because DCs are generally resistant to nonviral gene delivery methods. In contrast, we previously reported that AdRGD-mediated gene transfer into DCs has up to 98% efficiency. 17, 18 Whereas AdRGD is advantageous for gene transduction, several reports suggest that viral vector-mediated gene transduction induces cell death in target cells. 30 Our present findings demonstrated that AdRGD-Bcl-x L -and AdRGD-Bclx FNK -treated DCs are more resistant to naturally occurring cell death than AdRGD-Luc, suggesting that the antiapoptotic gene-transfer strategy could improve the viral vector-induced DC death. Based on these observations, it should be possible to further enhance the potency of DC-based vaccines through the combined use of AdRGD-mediated Bcl-x L or Bcl-x FNK gene transduction technology with other vaccine-enhancement techniques, such as a chemokine receptor gene (CCR7)-transduction strategy for more efficient accumulation of DCs in regional LNs or inflammatory cytokine gene expression. 31, 32 Thus, for the development of long-lived DCs for use in tumor immunotherapy, AdRGD-mediated gene transduction into DCs may offer important advantages over the conventional gene transduction methods currently in use.
In this study, we demonstrated that antigen-expressing DCs transduced with either the Bcl-x L or Bcl-x FNK gene as an antiapoptotic strategy offers an effective and potentially safer approach for prolonging the DC lifespan and the antigen-presentation period, as well as for 
T Yoshikawa et al increasing the potency of a DC-based tumor vaccine without oncogenic transformation. Thus, antiapoptotic cells engineered with AdRGD-mediated Bcl-x L or Bclx FNK gene transduction may provide an effective and potentially safe cell therapy in the near future. Furthermore, this antiapoptotic technology might also be highly useful for genetic manipulation of stem cells.
Materials and methods
Mice and cell lines
Female C57BL/6 and BALB/c-nu/nu mice (6-to 8-week old) were obtained from SLC Inc. (Hamamatsu, Japan). The C57BL/6 background Tg mouse line-expressing EGFP (EGFP-Tg mice) was kindly provided by Dr M Okabe (Osaka University, Suita, Japan). EL4 (murine thymoma cells; H- 2 b ) and E.G7-OVA cells (OVA cDNAtransfectant of EL4 cells) were purchased from the American Type Culture Collection (Manassas, VA, USA). EL4 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 50 mM 2-mercaptoethanol (2-ME) and antibiotics. E.G7-OVA cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 50 mM 2-ME and 400 mg ml À1 G418. CD8-OVA1.3 cells, a T-T hybridoma against the OVA 257-264 /H-2K b complex, were kindly provided from Dr CV Harding (Case Western Reserve University, Cleveland, OH, USA), 33 and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 50 mM 2-ME and antibiotics. A murine melanoma B16BL6 cell line derived from C57BL/6 mice (H-2 b ) was obtained from the JCRB cell bank (Tokyo, Japan) and cultured in minimum essential medium supplemented with 7.5% FBS and antibiotics. HEK293 cells (JCRB cell bank) were grown in DMEM supplemented with 10% FBS and antibiotics.
Generation of murine bone marrow-derived DCs
DCs were prepared according to the method of Lutz et al. 34 with slight modification. Briefly, bone marrow cells flushed from the femurs and tibias of C57BL/6 mice were seeded at 5 Â 10 6 cells per sterile 100-mm bacterial grade culture dish in 10 ml of RPMI 1640 containing 10% FBS, 40 ng ml À1 recombinant murine GM-CSF, 50 mM 2-ME and antibiotics. On day 3, another 10 ml of culture medium was added to the dish for medium replenishment. On day 6, 10 ml of the culture supernatant was collected and centrifuged at 1500 r.p.m. for 5 min at room temperature, and the pellet was resuspended in 10 ml of fresh culture medium, then returned to the original dish to conserve unattached cells. Nonadherent cells were harvested on days 6-8 as immature DCs. Phenotypic characterization of the DCs performed by flow cytometry using DC markers (CD11c, CD40, CD80 and CD86) and MHC molecules (class I and class II) indicated that more than 90% of the cells on days 7-9 of incubation with GM-CSF were DC marker-positive.
Preparation of recombinant AdRGD
The replication-deficient AdRGD-Bcl-x FNK and -Bcl-x L , which carried the mutant-or wild type-rat Bcl-x L gene derived from pEF1BOS-Bcl-x FNK and pEF1BOS-Bcl-x L , respectively 19 (kindly provided by Dr S Ohta, Nippon Medical School), were constructed by an improved in vitro ligation method using pAdHM15-RGD. [35] [36] [37] We also produced an AdRGD carrying a chicken-egg OVAexpressing (AdRGD-OVA) cDNA, human gp100 cDNA derived from pAx1-CA h-gp100 (kindly provided by Dr H Hamada, Sapporo Medical University, Sapporo, Japan; AdRGD-gp100) and firefly luciferase (AdRGDLuc), as described previously. 17, 31 All recombinant AdRGDs were propagated in HEK293 cells, purified by two rounds of cesium chloride gradient ultracentrifugation, dialyzed and stored at À80 1C. Titers of infective AdRGD particles (plaque-forming unit; PFU) were evaluated by an end-point dilution method using HEK293 cells.
AdRGD-mediated gene transduction into DCs
Immature DCs were suspended at a concentration of 5 Â 10 6 cells per ml in RPMI 1640 containing 5% FBS and placed in a 50 ml conical tube. Each AdRGD was added at various multiplicities of infection (MOI; PFU/cell), the suspension was mixed well and the tube was incubated at 37 1C for 2 h with occasional gentle agitation. The cells were washed three times with phosphate-buffered saline (PBS) and resuspended in a suitable solution.
DC survival assay
The Bcl-x FNK , Bcl-x L or luciferase-expressing DCs (designated FNK/DCs, Bcl-x L /DCs and Luc/DCs, respectively) were prepared using the corresponding AdRGDs at 25 MOI. These DCs were cultured at a density of 5 Â 10 4 cells per well on 96-well plates in GM-CSF-free RPMI 1640 for the number of days indicated in the figure. DC survival was quantified by measuring cell viability with PI staining under fluorescent microscopy on days 0, 2, 4 and 7, and was reported as the percentage of surviving cells relative to the number of total cells on day 0.
Antigen-presentation assays
DCs cotransduced with AdRGD-OVA and AdRGD-Bclx FNK (FNK+OVA/DC) or AdRGD-Bcl-x L (Bcl-x L +OVA/ DCs) were prepared using the corresponding AdRGDs at 25 MOI, and suspended in GM-CSF-free RPMI 1640. These DCs were seeded in a 96-well plate at a density of 10 5 cells per well and cultured for several days. On days 2, 4 and 7, the DCs were washed twice with PBS and fixed with 0.05% glutaraldehyde. Subsequently, the cells were cocultured with 10 5 CD8-OVA1.3 cells for 24 h at 37 1C. The response of stimulated CD8-OVA1.3 cells was assessed by determining the amount of IL-2 released into an aliquot of culture medium using a murine IL-2 ELISA kit (Biosource International, Camarillo, CA, USA). The AdRGD-OVA-transduced DCs (OVA/DC) or nontransduced DCs (mock DCs) were used as controls.
Tumor protection assay
We tested the antitumor efficacy of antiapoptotic proteinexpressing DCs using OVA, which is an artificial TAA. OVA/DCs, FNK+OVA/DCs and Bcl-x L +OVA/DCs transduced each at 25 MOI were cultured for 24 h. These transduced and mock DCs were intradermally injected into the left flank of C57BL/6 mice at 5 Â 10 4 cells per 50 ml. At 1 week after immunization, 1 Â 10 6 E.G7-OVA cells were intradermally inoculated into the right flanks of these mice. The major and minor axes of the resulting tumor were measured using microcalipers, and the Engineering of highly immunogenic long-lived DC vaccines T Yoshikawa et al tumor volume was calculated using the following formula: (tumor volume; mm 3 ) ¼ (major axis; mm) Â (minor axis; mm) 2 Â 0.5236. The mice were euthanized when one of the two measurements was greater than 20 mm. In the case of B16BL6 models, DCs cotransduced with AdRGD-gp100 and AdRGD-Bcl-x FNK (FNK+gp100/DC) or with AdRGD-gp100 alone (gp100/DCs) were prepared using the corresponding AdRGDs at 25 MOI, and then cultured for 24 h. C57BL/6 mice were immunized by intradermal injection of transduced DCs into the right flanks at 1.5 Â 10 6 cells, and then B16BL6 cells were inoculated into the left flank intradermally at 5 Â 10 4 cells 1 week post vaccination. The tumor size was examined using the same protocol as for the E.G7-OVA model.
51
Cr-release assay FNK+OVA/DC, Bcl-x L +OVA/DC, OVA/DC and mock DCs were intradermally injected into the left flanks of C57BL/6 mice at 2.5 Â 10 4 cells per 50 ml. Seven days later, nonadherent splenocytes were prepared from these mice and restimulated in vitro using E.G7-OVA cells, which were inactivated using 50 mg ml À1 mitomycin C (MMC) at 37 1C for 30 min, at a responder:stimulator ratio of 10:1 in RPMI 1640 supplemented with 10% FBS, 50 mM 2-ME, antibiotics and 10 U ml À1 murine recombinant IL-2. Five days after restimulation, the splenocytes were collected and used as effector cells. Cr released by detergent.
Intracellular cytokine staining assay
FNK+gp100/DC, gp100/DC and mock DCs were intradermally injected into the left flanks of C57BL/6 mice at 1.5 Â 10 6 cells per 50 ml. Seven days later, nonadherent splenocytes were prepared from these mice and restimulated with MMC-inactivated B16BL6 cells for 24 h. The number of IFN-g-secreting CD4
+ or CD8 + T cells was analyzed by intracellular cytokine staining as follows. First, the cell surface was stained with anti-CD8 (clone 53-6.7) and anti-CD4 (clone RM4-5) monoclonal antibodies (mAbs). The cells were then fixed and permeabilized (Cytofix/Cytoperm kit; BD Pharmingen, San Diego, CA, USA) and subsequently stained intracellularly with anti-IFN-g mAbs. Samples were fixed in PBS containing 2% paraformaldehyde and analyzed on a FACSCalibur flow cytometer, and data were analyzed using CellQuest software (Becton Dickinson, San Jose, CA, USA) with acquisition of 30 000 events. Similar results were obtained from two independent experiments. All antibodies used in this assay were purchased from BD Pharmingen.
In vivo antibody-mediated depletion
Ascites from BALB/c-nu/nu mice intraperitoneally injected with GK1.5 hybridoma (anti-CD4) or 53-6.72 hybridoma (anti-CD8) cells were kindly provided by Dr H Yamamoto (Osaka University, Suita, Japan). Mice were depleted of either CD4 + or CD8 + T cells by intraperitoneal injections of GK1.5 or 53-6.72 ascites cells. For NK cell depletions, 40 ml rabbit anti-asialo GM1 antisera (Wako Pure Chemical, Osaka, Japan) was intraperitoneally injected at a dose of 10 mg ml À1 in PBS. Depleting mAbs were injected on days 0, 3, 6, 9, 13 and 17. These mice were immunized by intradermal injection of transduced DCs into the right flanks at 1.5 Â 10 6 cells on day 0, and subcutaneously challenged with B16BL6 cells into the left flank intradermally at 5 Â 10 4 cells on day 7. Depletion was monitored by flow cytometry of peripheral lymphocytes isolated from mouse blood and stained with fluorescein isothiocyanate-conjugated anti-CD4, anti-CD8 or anti-NK1.1 (clones GK1.5, 53-6.7 and PK136, respectively; all from BD Pharmingen).
In vivo DC-migration assay EGFP-Tg mouse-derived DCs (EGFP-DC) were transduced with AdRGD-FNK or AdRGD-Luc at 25 MOI, and cultured for 24 h. These transduced cells (designated FNK/EGFP-DCs and Luc/EGFP-DCs, respectively) and mock EGFP-DCs were intradermally injected into the left flanks of wild-type C57BL/6 mice at 2 Â 10 6 cells per 50 ml. After 2, 4 and 8 days, the draining inguinal LNs were collected from these mice, fixed with 4% paraformaldehyde and then equilibrated by placing in graded concentrations of sucrose (10, 20, 30%) in PBS. Fixed specimens were embedded in Optimal Cutting Temperature compound (Sakura FineTek Japan Co. Ltd, Tokyo, Japan) and frozen in liquid nitrogen. Frozen thin sections (6 mm) were prepared, fixed with 4% paraformaldehyde and embedded in the Prolong Gold antifade reagent (Molecular Probes/Invitrogen, Carlsbad, CA, USA). The EGFP-positive cells were counted for each specimen under fluorescence microscopy (Bio-Zero; Keyence Co., Osaka, Japan).
